



# **Tuberculosis Country Profile 2021 Lao People's Democratic Republic**

*Source: Global tuberculosis report 2021. Geneva: World Health Organization*

*Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.*

# Tuberculosis profile: Lao People's Democratic Republic

Population 2020: 7.3 million

## Estimates of TB burden\*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	11 000 (7 000-16 000)	149 (97-213)
HIV-positive TB incidence	610 (390-870)	8.3 (5.3-12)
HIV-negative TB mortality	1 700 (1 000-2 400)	23 (14-33)
HIV-positive TB mortality	180 (110-260)	2.5 (1.5-3.6)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2020	74% (52-110)
TB patients facing catastrophic total costs, 2019	63% (58-67)
TB case fatality ratio (estimated mortality/estimated incidence), 2020	18% (9-28)

## TB case notifications, 2020

Total new and relapse	8 013
- % tested with rapid diagnostics at time of diagnosis	90%
- % with known HIV status	83%
- % pulmonary	94%
- % bacteriologically confirmed <sup>A</sup>	59%
- % children aged 0-14 years	1%
- % women (aged ≥15 years)	34%
- % men (aged ≥15 years)	65%
Total cases notified	8 122

## TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	369	5.6%
- on antiretroviral therapy	276	75%

## Drug-resistant TB care\*\*, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases <sup>A</sup>	89%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases <sup>A</sup>	100%
Laboratory-confirmed cases - MDR/RR-TB <sup>AA</sup>	49
Patients started on treatment - MDR/RR-TB <sup>AAA</sup>	39
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB <sup>AA</sup>	0
Patients started on treatment - pre-XDR-TB or XDR-TB <sup>AAA</sup>	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	35

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	90%	6 809
Previously treated cases, excluding relapse, registered in 2019	89%	118
HIV-positive TB cases registered in 2019	85%	290
MDR/RR-TB cases started on second-line treatment in 2018	84%	45
XDR-TB cases started on second-line treatment in 2018		0


## TB preventive treatment, 2020

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	10% (9.6-11)


## TB financing

National TB budget, 2021 (US\$ millions)	5
- Funding source, domestic	8.6%
- Funding source, international	46%
- unfunded	46%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




## HIV-negative TB mortality (Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2020 (Number)



## Cases attributable to five risk factors, 2020 (Number)



## Total budget (US\$ millions)



\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone

<sup>A</sup> Calculated for pulmonary cases only

<sup>AA</sup> Includes cases with unknown previous TB treatment history

<sup>AAA</sup> Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed